Related Experiment Video
Updated: Jul 18, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Tumour necrosis factor inhibitors--what we need to know
1Capital and Coast District Health Board. umbzaf@hotmail.com
Abstract:
Biologics have revolutionised the treatment of various autoimmune diseases. Earlier in 2006, New Zealand's Pharmaceutical Management Agency (PHARMAC) approved adalimumab (anti-tumour necrosis factor [TNF] agent) for treatment of severe, unresponsive rheumatoid arthritis in adult patients. Etanercept has been available for chronic juvenile arthritis in selected, younger patients in New Zealand. This review article describes some of the common adverse events related to anti-TNF inhibitors and the importance of establishing guidelines for surveillance in the New Zealand health system.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
